Granules India’s shares fell nearly 8% after the US FDA issued a warning letter regarding its Gagillapur facility, citing ...

Granules added that manufacturing and distribution of its existing products at the facility will continue unaffected.

"On February 26, 2025, the US FDA issued a Warning Letter to Granules' Gagillapur facility based on its inspection conducted ...

The USFDA issued a warning letter to Granules India Ltd's Gagillapur facility after an August 2024 inspection highlighted ...

Granules India has acquired Swiss CDMO company Senn Chemicals AG for Rs 192 crore, expanding its peptide therapeutics market ...

The Warning Letter is dated February 26, 2025 and the facility continues to hold an "Official Action Indicated" (OAI) status.

Drug firm Granules India Ltd on Thursday (February 27) announced that the US FDA has issued a Warning Letter for its ...

TP Solar Limited, Tata Power’s solar manufacturing arm, has bagged a Rs 632 crore worth contract from SECI. The Tata group ...

In a bid to break into the CDMO business at one of its most lucrative angles, India's Granules is snapping up Swiss contract ...

Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation ...

The development may temporarily delay the approval of pending product submissions from the site, but existing manufacturing ...

All sectoral indices ended in the red, posting losses between 1% and 10%. A majority of Nifty stocks delivered negative ...